GSK's Billion-Dollar Bet to Cure a Disease That's Stumped Medicine for Decades

Why Bepirovirsen Changes Everything

To understand why this deal matters, you need to understand how groundbreaking bepirovirsen's data already are.

In the B-Well 1 and B-Well 2 Phase 3 trials, bepirovirsen achieved functional cure in 19% of patients with a specific viral protein level (HBsAg) at or below 3,000 IU/mL. Among those with even lower baseline levels (under 1,000 IU/mL), the functional cure rate jumped to 26%. The placebo groups? Zero. Literally 0%.

That might not sound like a miracle at first glance. But remember: the current standard of care cures only a small fraction of patients. Going from near-zero to roughly 1 in 4 (in selected patients) is like going from horse-and-buggy to the automobile. Not a flying car yet, but a generational leap.

The data were published in the New England Journal of Medicine, which is the medical equivalent of getting your debut novel reviewed in the New York Times. The FDA has already given bepirovirsen both Fast Track and Breakthrough Therapy designations, regulatory signals that scream "we think this is important."

Jefferies analyst Michael Leuchten described bepirovirsen as the "key backbone for combination strategies" in hepatitis B and sees "clear blockbuster potential." GlobalData's Stephanie Kurdach called the results "transformative." William Blair analysts expect "broad uptake."

But not everyone is popping champagne. Leerink's Mani Foroohar flagged a real concern: screening bottlenecks and physician-office capacity could slow the launch. J.P. Morgan also struck a cautious note, saying investors will need full data to judge whether real-world uptake can match the hype.

The siRNA Piece: What JNJ-3989 Brings to the Table

JNJ-3989 has its own compelling dataset, mostly from Phase 2 studies. In clinical trials, it drove deep reductions in HBsAg (the key viral protein that the immune system needs to clear for a functional cure). In one cohort, 100% of patients who received at least 24 weeks of treatment saw meaningful HBsAg drops, and 88% dropped below 100 IU/mL.

Perhaps the most intriguing number: 39% of patients maintained their response for 48 weeks after their last dose. That kind of durability matters when you're trying to build a regimen that patients can eventually stop taking.

The drug was generally well tolerated at doses up to 400 mg, with no major safety signals flagged in the Phase 2 data. It doesn't have Phase 3 results yet, which is one reason J&J was willing to let it go; Janssen will continue funding the ongoing trials at its own expense while GSK takes over future development and commercialization.

The Science Behind the Combo: Why Two RNA Weapons Beat One

Here's why combining an ASO and an siRNA is more than just "more drugs = more better."

Both bepirovirsen (the ASO) and JNJ-3989 (the siRNA) target HBV's genetic material, but they use fundamentally different molecular pathways to do it. An ASO works through a mechanism called RNase H1, essentially flagging viral RNA for destruction by the cell's own cleanup crew. An siRNA works through something called RISC (RNA-induced silencing complex), a separate cellular machine that chops up the RNA in a different way.

Using both is like attacking a fortress through two different gates simultaneously. Early research on combining ASO and siRNA approaches in hepatitis B has shown deeper and more durable reductions in viral proteins than either approach alone. If bepirovirsen is already getting 19-26% functional cure rates solo, the hope is that adding JNJ-3989 could push those numbers significantly higher.

GSK's broader strategy extends beyond just these two drugs. The company is also running trials combining bepirovirsen with pegylated interferon (an immune-boosting therapy) and with its own immunotherapy candidates. The idea is an "antigen-down, immunity-up" approach: first, knock the virus's protein production to the floor using RNA-targeting drugs, then wake up the patient's immune system to finish the job.

GSK's RNA Shopping Spree

This isn't a one-off purchase. GSK has been on a deliberate RNA platform building spree. Beyond the JNJ-3989 deal, the company recently inked a deal worth over $1 billion with Frontier Biotechnologies for siRNA candidates targeting kidney disease. The pattern is clear: GSK sees RNA-based therapeutics as a core pillar of its future, not a side bet.

In hepatitis B specifically, GSK is now assembling what could become the most comprehensive cure-oriented pipeline in the industry. Bepirovirsen as the anchor. JNJ-3989 as the combination partner. Immunotherapies and interferon as potential add-ons. It's a modular system designed so that each new piece can theoretically boost the overall cure rate.

The Competition Is Real (and Crowded)

GSK isn't operating in a vacuum. The race for a hepatitis B functional cure has attracted some of the biggest names in pharma.

Vir Biotechnology has its own siRNA (xalnesiran) that, when combined with pegylated interferon, has shown 15-23% HBsAg loss rates in certain trial arms. Arbutus Biopharma is testing its siRNA imdusiran alongside a therapeutic vaccine, leaning into the antigen-down, immunity-up playbook. Gilead Sciences has a broad HBV pipeline including capsid modulators and TLR8 agonists. And a wave of Chinese companies (Brii Biosciences, Hengrui, Ribo Biotech, and others) are pushing their own siRNA programs forward rapidly.

But GSK has a crucial advantage: time. Bepirovirsen is the closest thing to an approved functional cure therapy in existence. If regulators greenlight it in Q4 2026, GSK will have established the clinical and regulatory precedent that everyone else will be measured against. First-mover advantage in a disease affecting a quarter billion people is not a small thing.

The Billion-Dollar Question

Can GSK actually pull this off? The science is promising, but the gap between "promising" and "blockbuster" is filled with real-world obstacles.

First, there's the screening problem. Most people with chronic hepatitis B don't even know they have it. Only about 13% of patients globally are diagnosed, and fewer than 4% are on treatment. You can't cure patients you haven't found.

Second, the regimen complexity. Injections, monitoring, sequential drug courses: this isn't as simple as a once-daily pill. That matters enormously in the highest-burden regions (sub-Saharan Africa, Southeast Asia) where healthcare infrastructure is thinnest.

Third, the combination data doesn't exist yet. GSK's Phase 2 trial of JNJ-3989 plus bepirovirsen hasn't started producing results. The entire thesis rests on the assumption that two RNA-targeting drugs will be better than one. That's a reasonable bet, but it's still a bet.

Still, the analysts seem to think the upside is worth the risk. Jefferies, William Blair, GlobalData, and others have used words like "blockbuster," "transformative," and "disruptor." Leerink called it an "under-appreciated blockbuster potential in the long term."

For 240 million people who've been told the best they can hope for is a lifetime of daily pills, even cautious optimism feels like a revolution. GSK is wagering a billion dollars that it can build the first real cure. The next 18 months will tell us whether that bet pays off.